SGPT (ALT) is the Appropriate Test for Evaluating Liver Function
For evaluating liver function, you should order SGPT (ALT), not PT (prothrombin time). These tests serve fundamentally different purposes in hepatic assessment.
Understanding the Distinction
SGPT/ALT: Marker of Hepatocellular Injury
- ALT is the primary marker for detecting hepatocellular damage and is highly specific for liver injury, as it is concentrated predominantly in hepatocytes 1, 2
- ALT elevations indicate active liver cell injury and are used to screen for and identify acute and chronic liver disease 3, 4
- Normal ALT ranges are 29-33 IU/L for males and 19-25 IU/L for females; levels above this warrant assessment 1, 4
- Elevated ALT has been associated with increased liver-related mortality, making it a critical screening tool 4
PT/INR: Marker of Hepatic Synthetic Function
- PT measures clotting factor production (factors II, V, VII, IX, X) and reflects synthetic function, not hepatocellular injury 1
- PT only becomes prolonged when there is loss of >70% of synthetic function, indicating severe or advanced liver disease 1
- PT can be elevated due to vitamin K deficiency (from fat malabsorption or cholestasis) independent of liver disease 1
- The INR was specifically designed and validated only for monitoring warfarin therapy, not as a general liver function test 5, 6
Clinical Algorithm for Liver Assessment
Initial screening should include:
- ALT and AST (hepatocellular injury markers)
- Alkaline phosphatase (cholestatic injury marker)
- Bilirubin (hepatic metabolism)
- Albumin and PT/INR (synthetic function - reserved for assessing severity in known liver disease) 1, 2
When to Order Each Test
Order ALT when:
- Screening for liver disease in asymptomatic or symptomatic patients
- Evaluating metabolic risk factors, medication effects, or alcohol use
- Monitoring known liver conditions
- The BALLETS study demonstrated that ALT and alkaline phosphatase identify the vast majority of adults with liver disease 1
Order PT/INR when:
- Assessing severity of established liver disease
- Evaluating for acute liver failure (PT <50% defines severe acute liver failure) 7
- Monitoring patients with decompensated cirrhosis
- Not for routine screening or predicting procedural bleeding risk in stable cirrhosis 8
Critical Pitfalls to Avoid
Do not use PT/INR as a screening test for liver disease - it only becomes abnormal with advanced hepatic dysfunction 1
Do not repeat PT/INR before routine procedures in stable cirrhotic patients - guidelines recommend against extensive preprocedural testing including repeated PT/INR measurements 8
Do not interpret INR in liver disease patients the same as warfarin patients - the standard INR scale is only validated for VKA monitoring, not liver disease assessment 5, 6
Baseline liver function testing should include ALT/SGPT for patients at risk for liver disease, including those with HIV, pregnant/postpartum women, chronic liver disease history, or regular alcohol use 9
The evidence consistently demonstrates that ALT (SGPT) is the appropriate initial test for evaluating liver function and detecting hepatocellular injury, while PT is reserved for assessing synthetic function in patients with known, advanced liver disease 1, 2, 3, 4.